JP5660561B2 - ジョイント部の潤滑に関するグリセロリン脂質の使用 - Google Patents
ジョイント部の潤滑に関するグリセロリン脂質の使用 Download PDFInfo
- Publication number
- JP5660561B2 JP5660561B2 JP2009529856A JP2009529856A JP5660561B2 JP 5660561 B2 JP5660561 B2 JP 5660561B2 JP 2009529856 A JP2009529856 A JP 2009529856A JP 2009529856 A JP2009529856 A JP 2009529856A JP 5660561 B2 JP5660561 B2 JP 5660561B2
- Authority
- JP
- Japan
- Prior art keywords
- joint
- dmpc
- cartilage
- phase transition
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000005461 lubrication Methods 0.000 title claims description 55
- 150000002327 glycerophospholipids Chemical class 0.000 title description 31
- 239000002502 liposome Substances 0.000 claims description 105
- 210000000845 cartilage Anatomy 0.000 claims description 93
- 150000003904 phospholipids Chemical group 0.000 claims description 79
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 64
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 64
- 239000007788 liquid Substances 0.000 claims description 61
- 230000007704 transition Effects 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 38
- 201000008482 osteoarthritis Diseases 0.000 claims description 30
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 26
- 239000012528 membrane Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229920002674 hyaluronan Polymers 0.000 claims description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 9
- 208000012659 Joint disease Diseases 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 3
- 208000018934 joint symptom Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims 2
- 206010060820 Joint injury Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 239000012071 phase Substances 0.000 description 65
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 41
- 150000002632 lipids Chemical class 0.000 description 36
- 150000003408 sphingolipids Chemical class 0.000 description 28
- 239000000314 lubricant Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 125000001183 hydrocarbyl group Chemical group 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 210000001188 articular cartilage Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 12
- 239000012530 fluid Substances 0.000 description 11
- 230000001050 lubricating effect Effects 0.000 description 11
- 239000000232 Lipid Bilayer Substances 0.000 description 10
- 230000003068 static effect Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 8
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 241000714177 Murine leukemia virus Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000219061 Rheum Species 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- -1 phospholipids Chemical class 0.000 description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 108010009030 lubricin Proteins 0.000 description 5
- 230000003349 osteoarthritic effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000001179 synovial fluid Anatomy 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000036487 Arthropathies Diseases 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 102100028965 Proteoglycan 4 Human genes 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical group OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 238000011540 hip replacement Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000013150 knee replacement Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical class ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 2
- YDIKCZBMBPOGFT-PWUSVEHZSA-N Malvidin 3-galactoside Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-PWUSVEHZSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- PXUQTDZNOHRWLI-QOPOCTTISA-O Primulin Natural products O(C)c1c(O)c(OC)cc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O3)cc3c(O)cc(O)cc3[o+]2)c1 PXUQTDZNOHRWLI-QOPOCTTISA-O 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- JTCWXISSLCZBQV-UHFFFAOYSA-N tribol Natural products CC(CO)CCC1OC2(O)CC3C4CC=C5CC(CCC5(C)C4CCC3(C)C2C1C)OC6OC(CO)C(OC7OC(C)C(O)C(O)C7O)C(O)C6OC8OC(C)C(O)C(O)C8O JTCWXISSLCZBQV-UHFFFAOYSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710097688 Probable sphingosine-1-phosphate lyase Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010082714 Silver Proteins Proteins 0.000 description 1
- 101710105985 Sphingosine-1-phosphate lyase Proteins 0.000 description 1
- 101710122496 Sphingosine-1-phosphate lyase 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- BQODPTQLXVVEJG-UHFFFAOYSA-N [O].C=C Chemical compound [O].C=C BQODPTQLXVVEJG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003010 carpal bone Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002411 hand bone Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940072322 hylan Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000000388 lateral force microscopy Methods 0.000 description 1
- JHDGGIDITFLRJY-UHFFFAOYSA-N laurdan Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CCCCCCCCCCC)=CC=C21 JHDGGIDITFLRJY-UHFFFAOYSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical group C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000000263 scanning probe lithography Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001137 tarsal bone Anatomy 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
Description
材料および方法
脂質:この研究で使用される脂質およびその供給源を図1に記載する;全てが純度>98%である。
(i)修正版バートレットアッセイを用いた(37,38)のリン脂質(PL)濃度、
(ii)サイズ分布であって、ALV−NIBSの高性能粒子寸法測定器(Langen、ドイツ)を用いた173°の散乱角度の動的光散乱による1μm未満のリポソームと、40nm〜2000μmの動的検出範囲となる偏光強度差散乱(polarization intensity differential scattering(PIDS))を備え付けたBdeckman Coulter LS Particle Size Analyzer 13−320(フラートン、カリフォルニア州)を用いた光回析による、400nmより大きなリポソームと、のサイズ分布と、
(iii)部分特異的断熱圧縮性であって、Barbuzenko et al(39)に記載されているように(39)、リポソーム散乱の密度(オーストリアのグラーツにあるAnton Paar社のDMA5000密度メータを用いる)と、リポソームを通過する5MHzの超音波の速度(イスラエルのエルサレムにあるNDT Instruments社のUCC−12超音波速度計を用いる)と、から計算した、部分特異的な断熱圧縮性と、
(iv)走査型電子顕微鏡(SEM)を用いた、構造と、
を特徴とする。
試験した表面活性リン脂質(SAPL)は、軟骨および骨液に天然に存在するホスファチジルコリンだった。
1. Alexander, CJ. Idiopathic osteoarthritis: time to change paradigms? Skeletal Radiol. 33, 321-324 (2004).
2. Corti, M.C. & Rigon, C. Epidemiology of osteoarthritis: prevalence, risk factors and functional impact. Aging CHn. Exp. Res. 15, 359-363 (2003).
3. Bullough, P.G. & Vigorita, VJ. Orthopaedic Pathology, Edn. 3rd. (Mosby- Wolfe, Baltimore; 1997).
4. Koopman, WJ. & Moreland, L.W. Arthritis and Allied Conditions: A Textbook of Rheumatology, Vol. 1-2, Edn. 15th. (Lippincott Williams & Wilkins, Philadelphia; 2005).
5. Sokoloff, L. The biology of degenerative joint disease. Acta Rhumatol BeIg. 1, 155-156 (1977).
6. Conaghan, P.G., Vanharanta, H. & Dieppe, PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann. Rheum. Dis. 64, 1539-1541 (2005).
7. Neame, R. & Doherty, M. Osteoarthritis update. CHn. Med. 5, 207-210 (2005).
8. Imhof, H. et al. Subchondral bone and cartilage disease: a rediscovered functional unit. Invest. Radiol. 35, 581-588 (2000).
9. Lajeunesse, D. & Reboul, P. Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. Curr. Opin. Rheumatol. 15, 628-633 (2003).
10. Radin, E.L. Who gets osteoarthritis and why? J. Rheumatol. Suppl. 70, 10- 15 (2004).
11. Grainger, R. & Cicuttini, F.M. Medical management of osteoarthritis of the knee and Mp joints. Med. J. Aust. 180, 232-236 (2004).
12. Swarm, D.A., Hendren, R.B., Radin, E.L., Sotman, S.L. & Duda, EA. The lubricating activity of synovial fluid glycoproteins. Arthritis Rheum. 24, 22-30 (1981).
13. Swarm, D. A. & Mintz, G. The isolation and properties of a second glycoprotein (LGP-II) from the articular lubricating fraction from bovine synovial fluid. Biochem. J. 179, 465-471 (1979).
14. Swarm, D.A., Slayter, H.S. & Silver, F.H. The molecular structure of lubricating glycoprotein-I, the boundary lubricant for articular cartilage. J. Biol. Chem. 256, 5921-5925 (1981).
15. Nitzan, D.W., Kreiner, B. & Zeltser, R. TMJ lubrication system: its effect on the joint function, dysfunction, and treatment approach. Compend. Contin. Educ. Dent. 25, 437-444 (2004).
16. Yui, N., Okano, T. & Sakurai, Y. Inflammation responsive degradation of crosslinked hyaluronic acid gels. J. Control. Release 22, 105-116 (1992).
17. Hills, B. A. & Butler, B. D. Surfactants identified in synovial fluid and their ability to act as boundary lubricants. Ann. Rheum. Dis. 43, 641-648 (1984).
18. Sarma, A. V., Powell, G.L. & LaBerge, M. Phospholipid composition of articular cartilage boundary lubricant. J. Orthop. Res. 19, 671-676 (2001).
19. Schwarz, LM. & Hills, B.A. Surface-active phospholipid as the lubricating component of lubricin. Br. J. Rheumatol. 37, 21-26 (1998).
20. Hills, B. A. & Monds, M.K. Enzymatic identification of the load-bearing boundary lubricant in the joint. Br. J. Rheumatol. 37, 137-142 (1998).
21. Ogston, A.G. & Stanier, J.E. Physiological function of hyaluronic acid in synovial fluid; viscous, elastic, and lubricant properties. J. Physiol. (Cambridge) 119, 244-252 (1953).
22. Benz, M., Chen, N. & Israelachvili, J. Lubrication and wear properties of grafted polyelectrolytes. hyaluronan and hylan, measured in the surface forces apparatus. J. Biomed. Mater. Res. A. 71, 6-15 (2004).
23. Rhee, D.K. et al. The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J. CHn. Invest. 115, 622- 631 (2005).
24. Swarm, D.A., Bloch, KJ., Swindell, D. & Shore, E. The lubricating activity of human synovial fluids. Arthritis Rheum. 27, 552-556 (1984).
25. Pickard, J.E., Fisher, J., Ingham, E. & Egan, J. Investigation into the effects of proteins and lipids on the frictional properties of articular cartilage. Biomaterials 19, 1807-1812 (1998).
26. Vecchio, P., Thomas, R. & Hills, BA. Surfactant treatment for osteoarthritis. Rheumatology (Oxford) 38, 1020-1021 (1999).
27. Gudimelta, O. A., Crawford, R. & Hills, BA. Consilidation responses of delipidized cartilage. Clin. Biomech. 19, 534-542 (2004).
28. Watanabe, M. et al. Ultrastructural study of upper surface layer in rat articular cartilage by "in vivo cryotechnique" combined with various treatments. Med. Elect. Microsc. 33, 16-24 (2000).
29. Kawano, T. et al. Mechanical effects of the intraarticular administration of high molecular weight hyaluronic acid plus phospholipid on synovial joint lubrication and prevention of articular cartilage degeneration in experimental osteoarthritis. Arthritis Rheum. 48, 1923-1929 (2003).
30. Forsey, R. W. et al. The effect of hyaluronic acid and phospholipid based lubricants on friction within a human cartilage damage model. Biomaterials 27, 4581-4590 (2006).
31. Klein, J. Molecular mechanisms of synovial joint lubrication. J. Proc. Inst. Mech Eng., Part J: J. Eng. Tribology 220, 691-710 (2006).
32. Briscoe, W.H. et al. Boundary lubrication under water. Nature 444, 191- 194 (2006).
33. Raviv, U. et al. Lubrication by charged polymers. Nature 425, 163-165 (2003).
34. Barenholz, Y. & Cevc, G. Structure and properties of membranes in Physical Chemistry of Biological Surfaces. (Marcel Dekker, New York; 2000).
35. Israelachvili, J., Intermolecular and surface Forces, 2nd edition,. Academic Pres, Lomdon (1992)
36. Marsh, D. CRC Handbook of Lipid Bilayers. (CRC Press, Boca Raton, FL; 1990).
37. Barenholz, Y. & Amselem, S. Quality control assays in the development and clinical use of liposome-based formulations in Liposome Technology, Edn. 2nd. (CRC, Boca Raton, FL; 1993).
38. Shmeeda, H., Even-Chen, S. & Barenholz, Y. Enzymatic assays for quality control and pharmacokinetics of liposome formulations: Comparison with nonenzymatic conventional methodologies. Methods Enzymol. 367, 272-292 (2003).
39. Garbuzenko, O., Barenholz, Y. & Priev, A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem. Phys. Lipids 135, 117-129 (2005).
40. Merkher, Y. et al. A rational human joint friction test using a human cartilage-on-cartilage arrangement. Tribol. Lett. 22, 29-36 (2006).
41. Barenholz, Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J. Liposome Res. 13, 1 (1993).
42. Bligh, E.G. & Dyer, W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol 37, 911-917 (1959).
43. Biltonen, R.L. & Lichtenberg, D. The use of differential scanning calorimetry as a tool to characterize liposome preparations. Chem. Phys. Lipids 64, 129-142 (1993).
44. Mouritsen, O. G. Life As a Matter of Fat. The Emerging Science of Lipidomics. (Springer- Verlag, Berlin; 2005).
45. Tirosh, O., Barenholz, Y., Katzhendler, J. & Priev, A. Hydration of polyethylene gly col-grafted liposomes. Biophys. J. 74, 1371-1379 (1998).
46. Hills, B.A. Boundary lubrication in vivo. J. Eng. Med. 214, 83-94 (2000).
47. Mabrey, S. & Sturtevant, J.M. Investigation of phase transitions of lipids and lipid mixtures by high sensitivity differential scanning calorimetry. PNAS 73, 3862-3866 (1976).
48. Yoshida, M., Zea-Aragon, Z., Ohtsuki, K., Ohnishi, M. & Ohno, S. Ultrastructural study of upper surface layer in rat mandibular condylar cartilage by quick-freezing method. Histol. Histopathol. 19, 1033-1041 (2004).
49. Klein, J. Mechanism of friction across molecularly confined films of simple liquids. Tribology Series 36, 59-64 (1999).
50. Maroudas, A. Distribution and diffusion of solutes in articular cartilage. Biophys. J. 10, 365-379 (1970).
51. Stockwell, R.A. & Barnett, CH. Changes in permeability of articular cartilage with age. Nature 201, 835-836 (1964).
52. Barnett, CH. & Palfrey, AJ. Absorption into the rabbit articular cartilage. J. Anat. 99, 365-375 (1965).
53. Faure, C, Bonakdar, L. & Dufourc, EJ. Determination of DMPC hydration in the L(alpha) and L(beta') phases by 2H solid state NMR of D2O. FEBS Lett. 405, 263-266 (1997).
54. Schrader, W. et al. Compressibility of lipid mixtures studied by calorimetry and ultrasonic velocity measurements. /. Phys. Chem. B 106, 6581-6586 (2002).
55. Schwarz, U.S., Komura, S. & Safran, S.A. Deformation and tribology of multi-walled hollow nanoparticles. Europhys. Lett. 50, 762-768 (2000).
56. Parasassi, T., Di Stefano, M., Loiero, M., Ravagnan, G. & Gratton, E. Cholesterol modifies water concentration and dynamics in phospholipid bilayers: a fluorescence study using Laurdan probe. Biophys J. 66, 763- 768 (1994).
57. Oncins, G., Garcia-Manyes, S. & Sanz, F. Study of frictional properties of a . phospholipid bilayer in a liquid environment with lateral force microscopy as a function of NaCl concentration. Langmuir 21, 7373-7349 (2005).
Claims (15)
- 平均直径が0.3μmより大きく、膜を含む多層ベシクル(MLV)であるリポソームを含む関節潤滑用の医薬組成物であって、ジミリストイルホスファチジルコリン(DMPC)、又はDMPCと1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)との混合物を含み、秩序固体(SO)から無秩序液体(LD)への相転移が生じる相転移温度を有し、当該相転移温度が20℃ないし39℃の温度内にあり、前記関節が前記相転移温度より高い関節温度を有することを特徴とする医薬組成物。
- 平均直径が0.3μmより大きく、膜を含む多層ベシクル(MLV)であるリポソームの使用であって、前記リボソームが、ジミリストイルホスファチジルコリン(DMPC)、又はDMPCと1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)との混合物を含む膜を含み、秩序固体(SO)から無秩序液体(LD)への相転移が生じる相転移温度を有し、当該相転移温度は、20℃ないし39℃の温度内にあり、相転移温度より高い関節温度を有する関節への投与用の医薬組成物を調製するためのリポソームの使用。
- 前記リポソームが0.3μmないし10μmの間の平均直径を有することを特徴とする請求項1に記載の医薬組成物。
- 前記多層ベシクル(MLV)が軟骨の摩耗を予防するために関節に投与されることを特徴とする請求項2に記載の使用。
- 前記リポソームが0.3μmないし10μmの間の平均直径を有することを特徴とする請求項2に記載の使用。
- 前記関節の温度が前記相転移温度より1ないし15℃高いことを特徴とする、請求項1又は3のいずれか1項に記載の医薬組成物。
- 前記リポソームが、関節内注射、関節鏡を用いた投与、又は外科的投与用に製剤化されることを特徴とする、請求項1、3、又は6のいずれか1項に記載の医薬組成物。
- 関節疾患又は関節疾患から生じる症状の治療用であることを特徴とする、請求項1、3、6,又は7のいずれか1項に記載の医薬組成物。
- 前記関節疾患が、関節炎、骨関節炎、リウマチ性関節炎患者の骨関節炎、外傷性関節損傷、関節固着、スポーツ外傷、ならびにその後の関節穿刺術、関節鏡手術、開き継手手術および関節置換術から選択されることを特徴とする、請求項8に記載の医薬組成物。
- 関節の潤滑を促進し、関節の摩耗を予防することを特徴とする請求項1に記載の医薬組成物。
- 関節固着、スポーツ外傷、骨関節炎(OA)に関する外傷性損傷又はリウマチ性関節炎に続発する疾患、及び乾癬性関節炎の治療、処置または悪化の予防のための請求項1、3、又は6ないし10いずれか1項に記載の医薬組成物。
- 関節温度を有し、生理学的に許容される賦形剤と平均直径が0.3μmより大きく、多層ベシクル(MLV)であるリポソームとを含む関節の関節潤滑のための医薬組成物であって、前記リポソームが少なくとも1つのリン脂質(PL)を含有する膜を含み、前記リン脂質がジミリストイルホスファチジルコリン(DMPC)、又はDMPCと1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)との混合物であり、前記膜が秩序固体(SO)から無秩序液体(LD)へと相転移が生じる相転移温度を有し、当該相転移温度が20℃ないし39℃内にあり、かつ前記関節温度よりも低いことを特徴とする医薬組成物。
- 前記生理学的に許容される賦形剤がヒスチジン緩衝液であることを特徴とする請求項12に記載の医薬組成物。
- 関節内注射、関節鏡を用いた投与または外科的投与による投与用の形状であることを特徴とする請求項12又は13に記載の医薬組成物。
- 前記リポソームはヒアルロン酸を含んでいないことを特徴とする、請求項1、3、又は6ないし14のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84765106P | 2006-09-28 | 2006-09-28 | |
PCT/IL2007/001215 WO2008038292A2 (en) | 2006-09-28 | 2007-10-07 | Use of glycerophospholipids for joint lubrication |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010540406A JP2010540406A (ja) | 2010-12-24 |
JP5660561B2 true JP5660561B2 (ja) | 2015-01-28 |
Family
ID=39144533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009529856A Active JP5660561B2 (ja) | 2006-09-28 | 2007-10-07 | ジョイント部の潤滑に関するグリセロリン脂質の使用 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8895054B2 (ja) |
EP (1) | EP2079442B1 (ja) |
JP (1) | JP5660561B2 (ja) |
CN (1) | CN101541308B (ja) |
CA (1) | CA2664944C (ja) |
ES (1) | ES2599630T3 (ja) |
IL (1) | IL197827A (ja) |
WO (1) | WO2008038292A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096140A2 (en) | 2003-04-25 | 2004-11-11 | The Penn State Research Foundation | Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
CN101541308B (zh) * | 2006-09-28 | 2012-02-01 | 哈达斯特医疗研究服务和开发有限公司 | 甘油磷脂用于关节润滑的用途 |
JP2010189315A (ja) * | 2009-02-18 | 2010-09-02 | Unitika Ltd | 関節軟骨損傷治癒促進剤及びそれを含有する飲食品 |
AU2010255391C1 (en) * | 2009-06-03 | 2016-10-27 | Sequessome Technology Holdings Limited | Formulations for the treatment of deep tissue pain |
WO2011022707A1 (en) | 2009-08-21 | 2011-02-24 | Henk-Andre Kroon | Vesicular formulations |
CA2803034A1 (en) | 2010-06-17 | 2011-12-22 | Jacob Klein | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
US8716204B2 (en) | 2010-07-27 | 2014-05-06 | Zimmer, Inc. | Synthetic synovial fluid compositions and methods for making the same |
RU2480174C1 (ru) * | 2011-11-22 | 2013-04-27 | Сергей Талустанович Сохов | Способ лечения заболеваний височно-нижнечелюстного сустава, сопровождающихся передним смещением и деформацией суставного диска |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
WO2013163407A1 (en) * | 2012-04-25 | 2013-10-31 | Trustees Of Tufts College | Silk microspheres and methods for surface lubrication |
EP3016637B1 (en) | 2013-07-04 | 2020-11-11 | Yeda Research and Development Co., Ltd. | Low friction hydrogels and hydrogel-containing composite materials |
US9982027B2 (en) | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
CN107073031B (zh) | 2014-06-15 | 2021-08-24 | 耶达研究及发展有限公司 | 利用水溶性聚合物和脂质/脂质体的表面处理 |
US10646574B2 (en) | 2014-07-21 | 2020-05-12 | Board Of Regents, The University Of Texas System | Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same |
IL234929B (en) | 2014-10-01 | 2021-01-31 | Yeda Res & Dev | Preparations containing liposomes and their use to prevent infections |
DK3316857T3 (da) | 2015-06-30 | 2021-10-18 | Sequessome Tech Holdings Limited | Multifasiske sammensætninger |
HRP20230566T1 (hr) * | 2017-08-22 | 2023-08-18 | Moebius Medical Ltd. | Liposomalna formulacija za podmazivanje zglobova |
RU2675343C1 (ru) * | 2018-03-22 | 2018-12-18 | Валерий Валентинович Бекреев | Способ малоинвазивного хирургического лечения внутренних нарушений височно-нижнечелюстного сустава, сопровождающихся смещением суставного диска, путем артроцентеза |
CN110314137B (zh) * | 2018-03-30 | 2022-04-05 | 北京泰德制药股份有限公司 | 一种含有脂质囊泡的冻干制剂 |
CN108743524B (zh) * | 2018-06-12 | 2020-10-30 | 清华大学 | 脂质体在润滑液中的应用、润滑液及其制备方法 |
TWI782181B (zh) * | 2019-02-11 | 2022-11-01 | 以色列商莫比斯醫療有限公司 | 用於關節潤滑的脂質體調配物 |
WO2020206314A1 (en) * | 2019-04-03 | 2020-10-08 | New York University | Liposomes encapsulating adenosine |
WO2023048097A1 (ja) * | 2021-09-21 | 2023-03-30 | 株式会社アイシン | 脂質膜小胞体およびその作製方法並びに作製装置 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5403592A (en) * | 1987-08-25 | 1995-04-04 | Macnaught Pty Limited | Lubricant composition for rheumatism |
KR940000166B1 (ko) * | 1989-11-09 | 1994-01-08 | 니혼다바고 상교오 가부시기가이샤 | 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜 |
AUPN723395A0 (en) * | 1995-12-19 | 1996-01-18 | Macnaught Medical Pty Limited | Lubrication methods |
US6800298B1 (en) * | 2000-05-11 | 2004-10-05 | Clemson University | Biological lubricant composition and method of applying lubricant composition |
NZ528544A (en) * | 2001-03-29 | 2006-03-31 | Scripps Research Inst | Formulations comprising entrapped active ingredients and uses thereof |
US20060029655A1 (en) * | 2001-06-25 | 2006-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for preparation of vesicles loaded with biological material and different uses thereof |
CA2451245A1 (en) * | 2001-06-25 | 2003-01-03 | Depuy International Limited | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
US6538032B1 (en) * | 2001-09-07 | 2003-03-25 | Charmzone Co., Ltd. | Phytosphingosine derivatives with antitumor activity |
US20030139344A1 (en) * | 2001-11-19 | 2003-07-24 | Mien-Chie Hung | Antitumor activity of Bok |
DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
US7205006B2 (en) * | 2003-09-25 | 2007-04-17 | Prime Pharmaceutical Corporation | Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same |
US7749485B2 (en) * | 2004-06-03 | 2010-07-06 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
CN101541308B (zh) * | 2006-09-28 | 2012-02-01 | 哈达斯特医疗研究服务和开发有限公司 | 甘油磷脂用于关节润滑的用途 |
US8834920B2 (en) * | 2006-12-21 | 2014-09-16 | Alza Corporation | Liposome composition for targeting egfr receptor |
MX2010008891A (es) * | 2008-02-20 | 2011-06-01 | Elc Man Llc | Composiciones topicas y metodos para blanquear la piel. |
JP2014512409A (ja) * | 2011-04-28 | 2014-05-22 | エスティーシー. ユーエヌエム | 標的送達用の多孔性ナノ粒子に担持された脂質二重層(プロトセル)及びその使用方法 |
-
2007
- 2007-10-07 CN CN2007800440724A patent/CN101541308B/zh active Active
- 2007-10-07 JP JP2009529856A patent/JP5660561B2/ja active Active
- 2007-10-07 WO PCT/IL2007/001215 patent/WO2008038292A2/en active Application Filing
- 2007-10-07 CA CA2664944A patent/CA2664944C/en active Active
- 2007-10-07 EP EP07827189.7A patent/EP2079442B1/en active Active
- 2007-10-07 ES ES07827189.7T patent/ES2599630T3/es active Active
-
2009
- 2009-03-26 US US12/411,855 patent/US8895054B2/en active Active
- 2009-03-26 IL IL197827A patent/IL197827A/en active IP Right Grant
-
2014
- 2014-10-22 US US14/520,542 patent/US20150037404A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008038292A2 (en) | 2008-04-03 |
CN101541308B (zh) | 2012-02-01 |
EP2079442A2 (en) | 2009-07-22 |
IL197827A0 (en) | 2009-12-24 |
US20150037404A1 (en) | 2015-02-05 |
JP2010540406A (ja) | 2010-12-24 |
EP2079442B1 (en) | 2016-07-27 |
IL197827A (en) | 2016-02-29 |
US8895054B2 (en) | 2014-11-25 |
CA2664944A1 (en) | 2008-04-03 |
ES2599630T3 (es) | 2017-02-02 |
CA2664944C (en) | 2016-06-14 |
US20100098749A1 (en) | 2010-04-22 |
CN101541308A (zh) | 2009-09-23 |
WO2008038292A3 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5660561B2 (ja) | ジョイント部の潤滑に関するグリセロリン脂質の使用 | |
Sivan et al. | Liposomes act as effective biolubricants for friction reduction in human synovial joints | |
Verberne et al. | Liposomes as potential biolubricant additives for wear reduction in human synovial joints | |
JP7383759B2 (ja) | 関節潤滑のためのリポソーム製剤 | |
Angayarkanni et al. | Lipid-bilayer assemblies on polymer-bearing surfaces: The nature of the slip plane in asymmetric boundary lubrication | |
TWI782181B (zh) | 用於關節潤滑的脂質體調配物 | |
EA042384B1 (ru) | Липосомальный состав для обеспечения смазывающей среды сустава | |
Shi | Investigations of cartilage lubricity and interactions between carbon nanotubes and phospholipid bilayers | |
Schroeder et al. | Surface Active Phospholipids as Cartilage Lubricants | |
BR122022020806B1 (pt) | Composição farmacêutica que compreende lipossomas, processo para a preparação da mesma e usos da dita composição para lubrificar uma articulação e tratar dor ou irritação em uma articulação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101006 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110701 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140807 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140930 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141028 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5660561 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |